The drug, GSBR-1290, belongs to the same class of treatments as Novo Nordisk’s blockbuster weight-loss drug Wegovy and Eli Lilly’s (LLY.N) diabetes drug Mounjaro.
After several rejections over 20-plus years, Fabre-Kramer Pharmaceuticals has secured the FDA’s approval for its major depressive disorder drug gepirone hydrochloride, now marketed under the brand name Exxua.
With Intercept’s failure to emerge as the non-alcoholic steatohepatitis market leader, Madrigal Pharmaceuticals is seeking to take leadership of the space fueled by a half-a-billion-dollar public offering.
AbbVie said on Friday a late-stage study of its experimental combination therapy to treat a form of blood cancer failed to meaningfully increase the survival rate of patients without the disease worsening.
Global health aid agency Unitaid has written to Johnson & Johnson’s CEO Joaquin Duato, urging “immediate action” to expand access to the company’s tuberculosis drug bedaquiline, which is protected by patents hindering generic alternatives.
The market opportunity for the drug is huge in the world’s most populous country, where obesity rates are high especially among women. Illegal copycat versions of Wegovy are already being sold through online sites.
The company and a former employee agreed to settle a lawsuit in which the worker claimed she was terminated after pointing out poor manufacturing practices and data falsification involving one of its blockbuster diabetes drugs, according to court filings.
Amicus Therapeutics’ treatment for a rare muscle disorder called Pompe disease was approved by the U.S. health regulator, the drugmaker said on Thursday, ending its years-long efforts to launch the therapy.
If approved, the therapy will help the U.S. drugmaker diversify its revenue stream as its blockbuster cancer immunotherapy, Keytruda, moves towards loss of market exclusivity in 2028.
J&J’s therapy combination of antibody treatment Rybrevant and experimental drug lazertinib showed a clinically meaningful improvement in progression-free survival rate in patients.